Oncodesign Precision Medicine Société anonyme (EPA: ALOPM)

France flag France · Delayed Price · Currency is EUR
0.636
+0.006 (0.95%)
Jan 17, 2025, 9:00 AM CET
-68.20%
Market Cap 11.56M
Revenue (ttm) 1.34M
Net Income (ttm) -7.79M
Shares Out 18.17M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,354
Average Volume 13,953
Open 0.634
Previous Close 0.630
Day's Range 0.634 - 0.650
52-Week Range 0.620 - 1.995
Beta -0.37
RSI 25.70
Earnings Date Dec 24, 2024

About EPA: ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s pipeline includes OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson’s disease. It is also developing drugs for the treatment of pancr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 19
Stock Exchange Euronext Paris
Ticker Symbol ALOPM
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.